Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05846789 · ClinicalTrials.gov registry record · Phase 2
SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers
A Phase 2 study of Metastatic Breast Cancer and Triple Negative Breast Cancer, sponsored by Kathy Miller.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 168
- Enrollment target
- 6
- Study locations
NCT05846789: Recruiting Phase 2 study of Metastatic Breast Cancer and Triple Negative Breast Cancer, sponsored by Kathy Miller.
NCT05846789 is a Phase 2 study of Metastatic Breast Cancer and Triple Negative Breast Cancer that is actively recruiting participants, run by Kathy Miller. The registered enrollment target is 168 participants, below the 204-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (18% lower). The trial reports 6 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05846789, a Phase 2 study of Metastatic Breast Cancer and Triple Negative Breast Cancer, is actively recruiting participants, sponsored by Kathy Miller.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 168 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is a randomized Phase II study of standard of care (SOC) chemotherapy monotherapy vs. SOC chemotherapy combined with tocilizumab in in Black and non-Black patients with metastatic triple negative or ER low breast cancer.
Conditions Studied
Interventions
- DRUG Tocilizumab
- DRUG SOC Chemotherapy
Study Locations (6)
Indiana
- IU Health Joe and Shelly Schwarz Cancer Center - Carmel
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center - Indianapolis
- Sidney and Lois Eskenazi Hospital - Indianapolis
Georgia
- Emory University - Atlanta
New York
- Roswell Park Comprehensive Cancer Center - Buffalo
North Carolina
- Duke University - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 168 participants |
| Start Date | 2024-07-02 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
What NCT05846789 shows while recruiting
NCT05846789 is an interventional study that assigns participants to a tested intervention. The registered 168 participants enrollment target is mid-sized for trials with a published cap, below the 204-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (18% lower).
The record links to 3 conditions, with Metastatic Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Tocilizumab is the first listed.
NCT05846789 lists 6 locations in 4 states (Indiana, Georgia, New York).
Frequently Asked Questions
What is clinical trial NCT05846789 about?
NCT05846789 is a clinical study titled "SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers". This is a randomized Phase II study of standard of care (SOC) chemotherapy monotherapy vs. SOC chemotherapy combined with tocilizumab in in Black and non-Black patients with metastatic triple negative or ER low breast cancer.
What is the current status of trial NCT05846789?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 168 participants. The study started on 2024-07-02. Estimated completion is 2026-12.
What conditions does trial NCT05846789 study?
This clinical trial studies the following conditions: Metastatic Breast Cancer, Triple Negative Breast Cancer, Estrogen-receptor-low Breast Cancer.
What interventions are being tested in trial NCT05846789?
The interventions under investigation include: Tocilizumab (DRUG), SOC Chemotherapy (DRUG).
Who is sponsoring clinical trial NCT05846789?
This trial is sponsored by Kathy Miller, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05846789 being conducted?
This trial has 6 study locations across Georgia, Indiana, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05846789's enrollment target sits among peer trials
168 40th of 139 higher than 100 of 139 other Metastatic Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Nurturing Exercise Routine for Greater Improvement in Zest and Energy on Enhertu
RECRUITING · Phase 2
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
RECRUITING · Phase 2
-
A Study of Surgery and Radiotherapy in People With Breast Cancer
RECRUITING · Phase 2
-
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
RECRUITING · Phase 2
-
A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02118922 · 168 participants
A Study to Test the Diagnostic Potential of Brillouin Microscopy for Corneal Ectasia
- NCT03536897 · 168 participants
IORT Following Breast Conserving Surgery for Early Stage Breast Cancer Registry
- NCT04078230 · 168 participants · NA
Regional or Extend LymphAdenectomy During Resection of Intrahepatic Cholangiocarcinoma
- NCT04159168 · 168 participants · NA
Facial Affect Sensitivity Training for Young Children With Callous-unemotional Traits
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI